Abstract
Tamoxifen (TMX) is a synthetic drug utilized for breast cancer treatment, but it has severe adverse impacts such as hepatic steatosis. The goal of this research was to discover the molecular prophylactic mechanisms of vitamins D-3 and/ or vitamin B12 versus pathogenesis of hepatic steatosis induced by TMX treatment in female rats. The results showed that co-administration of vitamins D-3 (0.5 mu g/kg, i.p.) and/ or vitamin B-12 (15 mu g/Kg, i.p.) to TMX (40 mg/Kg, orally)-treated rats, significantly ameliorated the alterations in the serum total lipid, hepatic triglycerides (TG), fatty acid translocase (CD36), peroxisome proliferator-activated receptor-gamma (PPAR-gamma), malondialdehyde (MDA), nitric oxide (NO), reduced glutathione (GSH), interleukin-6 (IL-6), tumor necrosis factor -alpha (TNF - alpha), transforming growth factor-beta (TGF-beta), C-reactive protein (CRP), caspase-3, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and albumin versus the normal rats. The present biochemical studies were confirmed by histopathological investigations. Conclusion, the present results may suggest that prophylactic treatment with vitamins D-3 and/ or vitamin B-12 may consider a promising protective therapy versus TMX induced hepatic steatosis and steatohepatitis in breast cancer patients as well as in subject at risk of incidence of liver steatosis.